Spots Global Cancer Trial Database for lymphoma, follicular
Every month we try and update this database with for lymphoma, follicular cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | NCT01263418 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, B-Cel... Lymphoma, Low-G... Lymphoma, Inter... | Ofatumumab | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | NCT01902862 | Lymphoma, Folli... | Bortezomib Rituximab | 18 Years - 70 Years | Janssen-Cilag G.m.b.H | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | NCT04370405 | Lymphoma, Folli... | YY-20394 | 18 Years - | Shanghai YingLi Pharmaceutical Co. Ltd. | |
| Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma | NCT00308087 | Lymphoma, Folli... | Sargramostim (L... Rituximab | 18 Years - | Sanofi | |
| Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma | NCT01208896 | Lymphoma, Folli... Stem Cell Trans... | Reduced_intensi... | 18 Years - 65 Years | University Hospital, Bordeaux | |
| A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma | NCT00315731 | Lymphoma, Folli... | Follicular Lymp... | 18 Years - | GlaxoSmithKline | |
| PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | NCT06290622 | Diffuse Large B... Lymphoma, B-Cel... Lymphoma, Folli... | Retifanlimab, I... | 18 Years - | University of Alabama at Birmingham | |
| A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | NCT00193492 | Lymphoma, Folli... | Bevacizumab Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma | NCT00724984 | Lymphoma Hodgkin Disease Lymphoma, Non-H... | PCI-24781 | 18 Years - | Pharmacyclics LLC. | |
| An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma | NCT01609036 | Lymphoma, Folli... | 18 Years - | Hoffmann-La Roche | ||
| Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | NCT02134262 | Relapsed or Ref... | Cyclophosphamid... Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3 | 20 Years - 70 Years | Jichi Medical University | |
| Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | NCT00494780 | Lymphoma, Folli... | Ofatumumab Cyclophosphamid... Doxorubicin Vincristine Prednisolone, P... | 18 Years - | GlaxoSmithKline | |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | NCT04911478 | Lymphoma, Folli... Lymphoma, Mantl... Marginal Zone L... Primary Mediast... Diffuse Large B... Lymphoma, Non-H... | ADI-001 | 18 Years - | Adicet Bio, Inc | |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | NCT02743546 | Leukemia, Lymph... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... | Duvortuxizumab Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | NCT03934567 | Lymphoma, Folli... | Abexinostat | 18 Years - | Xynomic Pharmaceuticals, Inc. | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea | NCT04036448 | Myelodysplastic... Lymphoma, Mantl... Lymphoma, Folli... | REVLIMID® | 19 Years - | Celgene | |
| A Study of Enzastaurin in Participants With Follicular Lymphoma | NCT00475644 | Lymphoma, Folli... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | NCT02257242 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, Mantl... Lymphoma, Small... Waldenstrom Mac... Lymphoma, B-Cel... | Rituximab Bendamustine Vincristine sul... | 18 Years - | Brown University | |
| Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma | NCT01208896 | Lymphoma, Folli... Stem Cell Trans... | Reduced_intensi... | 18 Years - 65 Years | University Hospital, Bordeaux | |
| Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma | NCT00915096 | Lymphoma, Folli... | 18 Years - 80 Years | Lymphoma Study Association | ||
| Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy | NCT01077518 | Lymphoma, Folli... | Ofatumumab Bendamustine in... Ofatumumab and ... Bendamustine in... | 18 Years - | Novartis | |
| A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | NCT02454270 | Leukemia, Lymph... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... Precursor Cell ... | Part 1 (Dose Es... Part 2 (Dose Ex... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Enzastaurin in Participants With Follicular Lymphoma | NCT00475644 | Lymphoma, Folli... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | NCT03057418 | Lymphoma, Non-H... Lymphoma, Folli... | Aurixim | 18 Years - | Biointegrator LLC | |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | NCT03310619 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | JCAR017 Durvalumab CC-122 Ibrutinib CC-220 Relatlimab Nivolumab CC-99282 | 18 Years - | Celgene | |
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | NCT05106192 | Mycosis Fungoid... Cutaneous T-cel... Non Hodgkin Lym... Lymphomatoid Pa... Lymphoma, Large... Lymphoma, Folli... | Med-Jet Injecto... Triamcinolone A... Bexarotene 1% T... Nitrogen Mustar... Conventional sy... | 18 Years - | Case Comprehensive Cancer Center | |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan | NCT05228158 | Lymphoma, Folli... | Tazemetostat | - | Eisai Inc. | |
| HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | NCT00394836 | Lymphoma, Folli... | Ofatumumab Ofatumumab | 18 Years - | GlaxoSmithKline | |
| Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon | NCT03087929 | Lymphoma, Folli... | Follow up | 18 Years - 65 Years | Sunnybrook Health Sciences Centre | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries | NCT05849857 | Lymphoma, Folli... | Mosunetuzumab | 18 Years - | Oslo University Hospital | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon | NCT03087929 | Lymphoma, Folli... | Follow up | 18 Years - 65 Years | Sunnybrook Health Sciences Centre | |
| Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma | NCT00915096 | Lymphoma, Folli... | 18 Years - 80 Years | Lymphoma Study Association | ||
| To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan | NCT02162771 | Lymphoma, Folli... | Rituxan CT-P10 Cyclophosphamid... Vincristine Prednisone | 18 Years - | Celltrion | |
| PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | NCT06290622 | Diffuse Large B... Lymphoma, B-Cel... Lymphoma, Folli... | Retifanlimab, I... | 18 Years - | University of Alabama at Birmingham | |
| A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) | NCT02278796 | Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... | BeEAM BEAM | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | NCT02631577 | Lymphoma, Folli... | Atezolizumab (M... Lenalidomide Obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | NCT00546793 | NHL Lymphoma, Non-H... Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Inter... Lymphoma, Large... Lymphoma, Low-G... Lymphoma, Mixed... Lymphoma, Small... Leukemia, Lymph... Leukemia, B-Cel... Leukemia, Proly... Leukemia, Small... Lymphoma, Small... Lymphoma, Lymph... Lymphoplasmacyt... CLL SLL | veltuzumab | 18 Years - | Gilead Sciences | |
| A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | NCT03357627 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | TAK-659 Venetoclax | 18 Years - | Calithera Biosciences, Inc | |
| Long-term Ovarian Fertility in Patients Treated for Lymphoma. | NCT05616325 | Lymphoma, Folli... | 18 Years - 45 Years | University Hospital, Lille | ||
| A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | NCT03934567 | Lymphoma, Folli... | Abexinostat | 18 Years - | Xynomic Pharmaceuticals, Inc. | |
| Long-term Ovarian Fertility in Patients Treated for Lymphoma. | NCT05616325 | Lymphoma, Folli... | 18 Years - 45 Years | University Hospital, Lille | ||
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | NCT02743546 | Leukemia, Lymph... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... | Duvortuxizumab Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan | NCT05228158 | Lymphoma, Folli... | Tazemetostat | - | Eisai Inc. | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | NCT06425302 | Lymphoma, Folli... | Golcadomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Bendamustine | 18 Years - | Celgene | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | NCT02343536 | Lymphoma, Large... Lymphoma, Folli... | Oral Azacitidin... Rituximab cyclophosphamid... Vincristine Prednisone | 18 Years - | Celgene | |
| Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon | NCT03087929 | Lymphoma, Folli... | Follow up | 18 Years - 65 Years | Sunnybrook Health Sciences Centre | |
| Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | NCT04982471 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | 18 Years - | Celgene | ||
| Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma | NCT00849654 | B-Cell Lymphoma B-Cell Leukemia | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, Large... Carcinoma, Non-... Carcinoma, Rena... Carcinoma, Squa... Malignant Melan... | PF-05082566 rituximab PF-05082566 | 18 Years - | Pfizer | |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | NCT02343536 | Lymphoma, Large... Lymphoma, Folli... | Oral Azacitidin... Rituximab cyclophosphamid... Vincristine Prednisone | 18 Years - | Celgene | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | NCT00319332 | Lymphoma, Small... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Non-H... | Ibritumomab Tiu... Iodine I 131 To... | 18 Years - | GlaxoSmithKline | |
| A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | NCT06045910 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Lymphoma, B-Cel... | ALETA-001 | 16 Years - | Cancer Research UK | |
| Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma | NCT01234766 | Lymphoma, Folli... | Bendamustine Rituximab Y-90 ibritumoma... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | NCT00060671 | Lymphoma, Folli... Lymphoma, Mixed... Lymphoma, Small... Lymphoma, Low-G... | rituximab Pixantrone (BBR... | 18 Years - | CTI BioPharma | |
| An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma | NCT01609036 | Lymphoma, Folli... | 18 Years - | Hoffmann-La Roche | ||
| To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan | NCT02162771 | Lymphoma, Folli... | Rituxan CT-P10 Cyclophosphamid... Vincristine Prednisone | 18 Years - | Celltrion | |
| Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) | NCT01250223 | Lymphoma, Folli... | 18 Years - | Associazione Angela Serra per la ricerca sul cancro | ||
| A Phase 1 Study of ADI-001 in B Cell Malignancies | NCT04735471 | Lymphoma, Folli... Lymphoma, Mantl... Marginal Zone L... Primary Mediast... Diffuse Large B... Lymphoma, Non-H... | ADI-001 Fludarabine Cyclophosphamid... | 18 Years - | Adicet Bio, Inc | |
| Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | NCT00384111 | Follicular Lymp... Lymphoma, Folli... | Zevalin Therape... R-CVP | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | NCT02743546 | Leukemia, Lymph... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... | Duvortuxizumab Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | NCT01950273 | Lymphoma, Folli... | BI 695500 MabThera | 18 Years - | Boehringer Ingelheim | |
| Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma | NCT01234766 | Lymphoma, Folli... | Bendamustine Rituximab Y-90 ibritumoma... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | NCT00384111 | Follicular Lymp... Lymphoma, Folli... | Zevalin Therape... R-CVP | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) | NCT00427856 | Lymphoma, Folli... | Obatoclax mesyl... Rituximab | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | NCT01902862 | Lymphoma, Folli... | Bortezomib Rituximab | 18 Years - 70 Years | Janssen-Cilag G.m.b.H | |
| A Phase II Study of Doxycycline in Relapsed NHL | NCT02086591 | Adult Diffuse L... Mantle Cell Lym... Lymphoma, Folli... Marginal Zone B... Malignant Lymph... Waldenstrom Mac... Small Lymphocyt... Chronic Lymphoc... T-Cell Lymphoma | Doxycycline | 18 Years - | University of Rochester | |
| An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma | NCT02413489 | Lymphoma, Mantl... Lymphoma, Large... Lymphoma, Folli... | Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | NCT05106192 | Mycosis Fungoid... Cutaneous T-cel... Non Hodgkin Lym... Lymphomatoid Pa... Lymphoma, Large... Lymphoma, Folli... | Med-Jet Injecto... Triamcinolone A... Bexarotene 1% T... Nitrogen Mustar... Conventional sy... | 18 Years - | Case Comprehensive Cancer Center | |
| A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma | NCT02809053 | Lymphoma, Folli... | SAIT101 MabThera® | 18 Years - | Archigen Biotech Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
